Ken Griffin Exagen Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exagen Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,100 shares of XGN stock, worth $3,806. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,100
Previous 4,500
75.56%
Holding current value
$3,806
Previous $13,000
69.23%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XGN
# of Institutions
43Shares Held
6.05MCall Options Held
1.1KPut Options Held
6.4K-
Rtw Investments, LP New York, NY1.51MShares$5.23 Million0.1% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A6891KShares$3.08 Million0.01% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY535KShares$1.85 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA491KShares$1.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY484KShares$1.67 Million0.0% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $56.3M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...